Everand Logo

Welcome to Everand!

  • STAT

    After forced sale, PatientsLikeMe founder frets that U.S. policy could chill collaboration in biotech

    PatientsLikeMe founder speaks publicly for the first time about the U.S. order that the company must find a new buyer.
    by Matthew Herper May 20, 2019 4 minutes
    Source: DANIEL LEAL-OLIVAS/AFP/Getty Images

    Jamie Heywood is a live wire of a man, a thin, energetic mechanical engineer who entered the biotech world after his brother was diagnosed with amyotrophic lateral sclerosis in 1998. Seeing the state of basic science around the disease, he started the world’s first nonprofit biotechnology company, ALS TDI, with his family. From that moment, he was never one to mince words.

    So he made his frustration clear when he spoke for the first time publicly about what has been happening to his second company, PatientsLikeMe, which is being an investment by China-based iCarbonX. At the conference where Heywood appeared recently, the Convergence Forum on Cape Cod, the room took on the tenor of a wake as he spoke about the

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
    A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
    Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

    Related Books & Audiobooks